


# LIFE SCIENCE TREND ANALYSIS

SWITZERLAND | 2024



VENTURE VALUATION  
GLOBAL VALUATION SERVICES

**BASEL  
AREA**   
MORE TO DISCOVER

*life science zurich*  
*business network*



JULY 2024

# ABOUT US



The following statistical information has been obtained from Biotechgate, a global, comprehensive life science database encompassing the biotechnology, pharmaceutical and medical device industries.

[www.biotechgate.com](http://www.biotechgate.com)



The Swiss Life Sciences Database is a part of the global Biotechgate and is brought to you in partnership with Swiss Biotech Association, Basel Area Business & Innovation and Life Science Zurich/Innovation Zurich.

[www.swisslifesciences.com](http://www.swisslifesciences.com)



Biotechgate is owned and operated by Venture Valuation AG, a Zurich based company specializing in independent assessment and valuation of technology-driven companies in high growth industries, such as the life sciences (biotech, pharma, medtech), ICT, high-tech, nanotech, cleantech and renewable energy.



[www.venturevaluation.com](http://www.venturevaluation.com)

# OUR PARTNERS



# OVERVIEW OF THE LIFE SCIENCE INDUSTRY



## NUMBER OF COMPANIES BY SECTOR



For the definition of categories please visit [www.biotechgate.com/web/cms/index.php/covered\\_industry\\_sectors.html](http://www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html). Biotech Companies include the following categories: Biotechnology – Therapeutics and Diagnostics; Biotechnology – R&D; Biotechnology – Other. \*Other life science related companies include supplier & engineering, professional services & consulting, media and public / non-profit organizations / medical facilities. Professional services & consulting includes 7 companies of the category "Media". Percentage value is expressed as % of total number of companies. Information displayed may alter as new information is received continuously


# OVERVIEW OF BIOTECH COMPANIES

## NUMBER OF COMPANIES BY SECTOR



# CANTONAL OVERVIEW OF THE LIFE SCIENCE INDUSTRY


## NUMBER OF LIFE SCIENCE COMPANIES BY TOP 5 CANTONS



Displayed are the five Swiss cantons with the highest number of life science companies in the displayed categories. For the definition of categories please visit [www.biotechgate.com/web/cms/index.php/covered\\_industry\\_sectors.html](http://www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html). Biotech - T&D category equals to Biotechnology - Therapeutics and Diagnostics. Information displayed may alter as new information is received continuously.

# BIOTECH - THERAPEUTICS COMPANIES BY KEY ACTIVITIES

AS PERCENTAGE OF TOTAL NUMBER OF BIOTECH - THERAPEUTICS COMPANIES




For 337 Biotech Therapeutics companies there were 619 subsectors (key activity areas) assigned (one biotech company can be active in multiple areas). The graph displays Biotech – Therapeutics and Diagnostics subsectors as the percentage of the total number of Biotech – Therapeutics and Diagnostics subsectors with exclusion of the category Others and categories with a percentage of less than 2%. The company subsectors are regarded as the key activities of a company. For the definition of subsectors please visit [www.biotechgate.com/web/cms/index.php/covered\\_industry\\_sectors.html](http://www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html). Information displayed may alter as new information is received continuously.


# BIOTECH ASSETS IN CLINICAL DEVELOPMENT

BY INDICATION AND DEVELOPMENT PHASE

## BREAKDOWN BY INDICATION



## BREAKDOWN BY DEVELOPMENT PHASE




Both graphs contain the number of assets of Biotech – Therapeutics and Diagnostics companies (excl. of Pharma or Biotech – Others or Biotech R&D Services companies). Products in Discovery and Lead Optimization Phase are merged into Preclinical; Development Phase I/II trials are merged into Phase II and Phase II/III trials are merged into Phase III category. Information displayed in the chart may alter as new information is received continuously.




# ASSETS AVAILABLE FOR OUT-LICENSING

## NUMBER OF ASSETS

### BY ASSET CLASS




### THERAPEUTICS IN DEVELOPMENT BY DEVELOPMENT PHASE



The graph titled Therapeutics in Development by Development Phase displays a subset of the asset class Therapeutics. Products in Discovery and Lead Optimization Phase are merged into Preclinical; Development Phase I/II trials are merged into Phase II and Phase II/III trials are merged into Phase III category.

# OVERVIEW OF OWNERSHIP


## PERCENTAGE OF TOTAL NUMBER OF COMPANIES BY OWNERSHIP AND SECTOR



For the definition of categories please visit [www.biotechgate.com/web/cms/index.php/covered\\_industry\\_sectors.html](http://www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html). Biotech- T&D stands for Biotechnology – Therapeutics & Diagnostics. Percentage value is expressed as % of total number of companies in the sector. Information displayed may alter as new information is received continuously.

# COMPANY FOUNDATION TIMELINE

NUMBER OF LIFE SCIENCE COMPANIES FOUNDED BY YEAR | 2013-2022




The graph contains the number of privately owned or publicly listed (no subsidiaries) life science companies founded by year including Biotech - Therapeutic and Diagnostic, Biotech - R&D Services, Biotech - Others, Pharma, Medical Technology and Digital Health companies. **Companies founded in 2023 were excluded** since newly founded companies often remain under the radar until their first financing round. Information displayed in the chart may alter as new information is received continuously.

# VENTURE FINANCING OF LIFE SCIENCE COMPANIES

## PRIVATE EQUITY ROUNDS | 2022-2023

### LIFE SCIENCE COMPANIES




### BIOTECH COMPANIES



Life Science companies include Biotech - Therapeutics and Diagnostics, Biotech - R&D Services, Biotech - Others, Pharma, Medical Technology and Digital Health companies. Biotech companies are a subset of Life Science companies and include: Biotech - Therapeutics and Diagnostics, Biotech - R&D Services, Biotech - Others. Financing data only includes private equity rounds (excl. private placements in public companies). Data may alter as new information is continuously received and/or new tranches to existing financing rounds are added.

# CANTONAL VENTURE FINANCING OF LIFE SCIENCE COMPANIES


## PRIVATE EQUITY ROUNDS BY TOP 5 CANTONS | 2022-2023



The graph displays the top 5 Swiss cantons in terms of the total amount of private equity financing of life science companies for 2022 and 2023. Life science companies include Biotech - Therapeutics and Diagnostics, Biotech - R&D Services, Biotech - Others, Pharma, Medical Technology and Digital Health companies. . Biotech companies are a subset of Life Science companies and include: Biotech - Therapeutics and Diagnostics, Biotech - R&D Services, Biotech - Others. Data may alter as new information is continuously received and/or new tranches to existing financing rounds are added.

# BIOTECH VENTURE FINANCING


## PRIVATE EQUITY ROUNDS – 5 YEAR REPORT



Biotech companies are a subset of Life Science companies and include: Biotech- Therapeutic and Diagnostic, Biotech- R&D Services, Biotech – Others. Financing data only includes private equity rounds (excl. private placements in public companies) of biotech companies (incl. therapeutic and diagnostic, R&D services and others). Data may alter as new information is continuously received and/or new tranches to existing financing rounds are added.

# BIOTECH IPOs






## SWISS BIOTECH COMPANIES THAT WENT PUBLIC WORLDWIDE (2020-2023)



Included are Biotechnology – Therapeutics and Diagnostics, Biotechnology – R&D services, and Biotech – Other companies, Pharma (fully integrated), Medical Technology, and Digital Health companies. Data may alter as new information is continuously received.

# MAJOR BIOTECH VENTURE FINANCING ROUNDS (2023)

## TOP 5 PRIVATE EQUITY FINANCING ROUNDS | 2023











Company	Sector	Most Advanced Asset Phase	Type of Round	USD M
<b>Noema Pharma AG</b> 	Biotech – Therapeutics	II	Series B	\$112
<b>Alentis Therapeutics AG</b> 	Biotech – Therapeutics	I	Series C	\$105
<b>Rejuveron Life Sciences AG</b> 	Biotech – Therapeutics	N/A	Dual tranche Series B + convertible loan	\$75
<b>Nouscom AG</b> 	Biotech - Therapeutics	II	Series C	\$72
<b>TOLREMO therapeutics AG</b> 	Biotech - Therapeutics	Preclinical	Series A	\$39

The table shows the five biggest private equity financing rounds (excl. IPOs, research grants, loans) of private and independent Swiss biotech companies in 2023. Information displayed in the table may alter as new information is continuously received and/or new tranches to existing financing rounds are added.



# MAJOR BIOTECH AND PHARMA M&A DEALS (2023)

## TOP 5 M&A DEALS | 2023

Target	Buyer	Acquisition Type	USD M
Telavant, Inc. 	F. Hoffman-La Roche Ltd 	Entire Company	\$7250
Chinook Therapeutics Inc. 	Novartis AG 	Entire Company	\$3500
DTx Pharma, Inc. 	Novartis AG 	Entire Company	\$1000
Synaffix BV 	Lonza Group Ltd 	Entire Company	\$172
Trinity Biotech plc 	Biosynth 	Fitzgerald Industries life sciences supply business	\$30

The table shows the M&A deals of private and independent biotech and pharma companies in 2023, where one party (target or buyer company) is headquartered in Switzerland. Information displayed in the table may alter as new information is continuously received and/or new tranches to existing financing rounds are added.

# ABOUT BIOTECHGATE



**Biotechgate** is a leading **business development and licensing database** for the entire life science industry, offering a wealth of information on over 60,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for big pharma, start-ups, investors, and other industry professionals. Biotechgate also features 45,000 **licensing deals** and a **clinical trials database** containing over 920,000 records from registries around the world.

To register for a free trial access or to learn more about the different subscription options, please visit [www.biotechgate.com](http://www.biotechgate.com).

# BIOTECHGATE DIGITAL PARTNERING

Virtual business development & licensing event

Aug 26 – 30, 2024



[www.digitalpartnering.com](http://www.digitalpartnering.com)

# TERMS OF USE

The Life Sciences Trend Analysis is based on data entered in the Biotechgate Database available at [www.biotechgate.com](http://www.biotechgate.com). The statistics and graphs in this presentation are based on figures and information entered in this database and we do not guarantee any accuracy hereof.

The use of the figures and graphs provided in this report is free of charge for any presentations as long as [www.biotechgate.com](http://www.biotechgate.com) is clearly cited as the source. For all other uses please contact us for terms and conditions.



## BIOTECHGATE

*c/o Venture Valuation VV AG*

Kasernenstrasse 11

8004 Zurich

SWITZERLAND



+41 (43) 321 86 60



[www.venturevaluation.com](http://www.venturevaluation.com)